MX2008013308A - Nuevos derivados de arilaminopiridina heteroaril-sustituidos como inhibidores de mek. - Google Patents
Nuevos derivados de arilaminopiridina heteroaril-sustituidos como inhibidores de mek.Info
- Publication number
- MX2008013308A MX2008013308A MX2008013308A MX2008013308A MX2008013308A MX 2008013308 A MX2008013308 A MX 2008013308A MX 2008013308 A MX2008013308 A MX 2008013308A MX 2008013308 A MX2008013308 A MX 2008013308A MX 2008013308 A MX2008013308 A MX 2008013308A
- Authority
- MX
- Mexico
- Prior art keywords
- alkyl
- substituted
- hydrogen
- unsubstituted
- aryl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/79—Acids; Esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US79307306P | 2006-04-19 | 2006-04-19 | |
| PCT/US2007/009456 WO2007123936A1 (en) | 2006-04-19 | 2007-04-18 | Novel heteroaryl-substituted arylaminopyridine derivatives as mek inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2008013308A true MX2008013308A (es) | 2008-10-27 |
Family
ID=38357968
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2008013308A MX2008013308A (es) | 2006-04-19 | 2007-04-18 | Nuevos derivados de arilaminopiridina heteroaril-sustituidos como inhibidores de mek. |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US8076486B2 (enExample) |
| EP (1) | EP2013180A1 (enExample) |
| JP (1) | JP5525812B2 (enExample) |
| KR (1) | KR20090005195A (enExample) |
| CN (2) | CN101426766B (enExample) |
| AR (1) | AR060807A1 (enExample) |
| AU (1) | AU2007240860A1 (enExample) |
| BR (1) | BRPI0711625A2 (enExample) |
| CA (1) | CA2644425A1 (enExample) |
| EA (1) | EA200802050A1 (enExample) |
| IL (1) | IL194546A0 (enExample) |
| MX (1) | MX2008013308A (enExample) |
| WO (1) | WO2007123936A1 (enExample) |
| ZA (1) | ZA200807263B (enExample) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007123939A2 (en) * | 2006-04-19 | 2007-11-01 | Laboratoires Serono S.A. | Novel arylamino n-heteraryls as mek inhibitors |
| EP2231636B1 (en) * | 2007-12-07 | 2011-09-14 | Novartis AG | Pyrazole derivatives and use thereof as inhibitors of cyclin dependent kinases |
| US9084781B2 (en) | 2008-12-10 | 2015-07-21 | Novartis Ag | MEK mutations conferring resistance to MEK inhibitors |
| WO2011106298A1 (en) | 2010-02-25 | 2011-09-01 | Dana-Farber Cancer Institute, Inc. | Braf mutations conferring resistance to braf inhibitors |
| BR112012022801B8 (pt) | 2010-03-09 | 2019-10-29 | Dana Farber Cancer Inst Inc | método de identificar um indivíduo que tem câncer que é provável beneficiar-se do tratamento com uma terapia de combinação com um inibidor de raf e um segundo inibidor e uso de um inibidor de raf e um segundo inibidor para a fabricação de um medicamento para tratar câncer |
| US9133123B2 (en) | 2010-04-23 | 2015-09-15 | Cytokinetics, Inc. | Certain amino-pyridines and amino-triazines, compositions thereof, and methods for their use |
| AR081331A1 (es) | 2010-04-23 | 2012-08-08 | Cytokinetics Inc | Amino- pirimidinas composiciones de las mismas y metodos para el uso de los mismos |
| AR081626A1 (es) | 2010-04-23 | 2012-10-10 | Cytokinetics Inc | Compuestos amino-piridazinicos, composiciones farmaceuticas que los contienen y uso de los mismos para tratar trastornos musculares cardiacos y esqueleticos |
| US8759380B2 (en) | 2011-04-22 | 2014-06-24 | Cytokinetics, Inc. | Certain heterocycles, compositions thereof, and methods for their use |
| US20150141470A1 (en) | 2012-05-08 | 2015-05-21 | The Broad Institute, Inc. | Diagnostic and treatment methods in patients having or at risk of developing resistance to cancer therapy |
| WO2014007228A1 (ja) | 2012-07-03 | 2014-01-09 | 小野薬品工業株式会社 | ソマトスタチン受容体作動活性を有する化合物およびその医薬用途 |
| KR20170125931A (ko) * | 2015-03-10 | 2017-11-15 | 오리진 디스커버리 테크놀로지스 리미티드 | 면역조절제로서의 3-치환된 1,3,4-옥사다이아졸 및 티아다이아졸 화합물 |
| TN2017000483A1 (en) | 2015-05-20 | 2019-04-12 | Amgen Inc | Triazole agonists of the apj receptor. |
| WO2017033113A1 (en) | 2015-08-21 | 2017-03-02 | Acerta Pharma B.V. | Therapeutic combinations of a mek inhibitor and a btk inhibitor |
| US10150754B2 (en) * | 2016-04-19 | 2018-12-11 | Celgene Quanticel Research, Inc. | Histone demethylase inhibitors |
| WO2017192485A1 (en) | 2016-05-03 | 2017-11-09 | Amgen Inc. | Heterocyclic triazole compounds as agonists of the apj receptor |
| WO2018097945A1 (en) | 2016-11-16 | 2018-05-31 | Amgen Inc. | Heteroaryl-substituted triazoles as apj receptor agonists |
| US10906890B2 (en) | 2016-11-16 | 2021-02-02 | Amgen Inc. | Triazole phenyl compounds as agonists of the APJ receptor |
| WO2018093580A1 (en) | 2016-11-16 | 2018-05-24 | Amgen Inc. | Triazole pyridyl compounds as agonists of the apj receptor |
| EP3541792B1 (en) | 2016-11-16 | 2020-12-23 | Amgen Inc. | Triazole furan compounds as agonists of the apj receptor |
| MA46827A (fr) | 2016-11-16 | 2019-09-25 | Amgen Inc | Composés de triazole à substitution cycloalkyle en tant qu'agonistes du récepteur apj |
| US11191762B2 (en) | 2016-11-16 | 2021-12-07 | Amgen Inc. | Alkyl substituted triazole compounds as agonists of the APJ Receptor |
| WO2018204532A1 (en) | 2017-05-03 | 2018-11-08 | Vivace Therapeutics, Inc. | Non-fused tricyclic compounds |
| JP7245229B2 (ja) | 2017-08-21 | 2023-03-23 | ビバーチェ セラピューティクス，インク． | ベンゾスルホニル化合物 |
| WO2019089335A1 (en) | 2017-11-03 | 2019-05-09 | Amgen Inc. | Fused triazole agonists of the apj receptor |
| EP3720430A4 (en) | 2017-12-06 | 2021-05-05 | Vivace Therapeutics, Inc. | BENZOCARBONYL COMPOUNDS |
| BR112020011162A2 (pt) * | 2017-12-07 | 2020-11-17 | Amplyx Pharmaceuticals, Inc. | agentes antifúngicos derivados de piridina substituída por heterociclo |
| CN110317190A (zh) * | 2018-03-28 | 2019-10-11 | 首都医科大学 | 一种三唑-羧酸酯类衍生物在医药领域的应用 |
| WO2019213006A1 (en) | 2018-05-01 | 2019-11-07 | Amgen Inc. | Substituted pyrimidinones as agonists of the apj receptor |
| EP3793551A4 (en) | 2018-05-16 | 2022-01-26 | Vivace Therapeutics, Inc. | OXADIAZOLE COMPOUNDS |
| AU2020242287A1 (en) | 2019-03-21 | 2021-09-02 | INSERM (Institut National de la Santé et de la Recherche Médicale) | A Dbait molecule in combination with kinase inhibitor for the treatment of cancer |
| KR20220098759A (ko) | 2019-11-08 | 2022-07-12 | 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) | 키나제 억제제에 대해 내성을 획득한 암의 치료 방법 |
| EP4061364A4 (en) * | 2019-11-20 | 2023-09-13 | Vivace Therapeutics, Inc. | HETEROARYL COMPOUNDS |
| WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
| JP2024521788A (ja) | 2021-05-27 | 2024-06-04 | ミラティ セラピューティクス， インコーポレイテッド | 併用療法 |
| WO2025054260A1 (en) * | 2023-09-07 | 2025-03-13 | Kinnate Biopharma Inc. | Inhibitors of mek kinase |
| WO2025073765A1 (en) | 2023-10-03 | 2025-04-10 | Institut National de la Santé et de la Recherche Médicale | Methods of prognosis and treatment of patients suffering from melanoma |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL144215A0 (en) | 1999-01-13 | 2002-05-23 | Warner Lambert Co | 1-heterocycle substituted diarylamines |
| GB2373245A (en) * | 2001-03-12 | 2002-09-18 | Bayer Ag | Pyridinyl pyrazoles and their use for the treatment of COPD |
| CA2498281A1 (en) * | 2002-09-10 | 2004-03-25 | Pharmacia Italia S.P.A. | Substituted pyridine derivatives as antitumor agent |
| AU2003293376A1 (en) * | 2002-12-10 | 2004-06-30 | Imclone Systems Incorporated | Anti-angiogenic compounds and their use in cancer treatment |
| US20050004186A1 (en) | 2002-12-20 | 2005-01-06 | Pfizer Inc | MEK inhibiting compounds |
| AU2004229392A1 (en) * | 2003-04-09 | 2004-10-28 | Exelixis, Inc. | Tie-2 modulators and methods of use |
| WO2005000818A1 (en) | 2003-06-27 | 2005-01-06 | Warner-Lambert Company Llc | 5-substituted-4-`(substituted phenyl)!amino!-2-pyridone deviatives for use as mek inhibitors |
| WO2005004818A2 (en) * | 2003-07-09 | 2005-01-20 | Imclone Systems Incorporated | Heterocyclic compounds and their use as anticancer agents |
| JP4768628B2 (ja) | 2003-11-19 | 2011-09-07 | アレイ バイオファーマ、インコーポレイテッド | Ｍｅｋの二環系阻害剤及びその使用方法 |
| PT1802579E (pt) * | 2004-10-20 | 2014-02-17 | Merck Serono Sa | Derivados da 3-arilaminopiridina |
-
2007
- 2007-04-18 ZA ZA200807263A patent/ZA200807263B/xx unknown
- 2007-04-18 CN CN200780014073.4A patent/CN101426766B/zh not_active Expired - Fee Related
- 2007-04-18 CN CN201210488042.5A patent/CN103121996B/zh not_active Expired - Fee Related
- 2007-04-18 AU AU2007240860A patent/AU2007240860A1/en not_active Abandoned
- 2007-04-18 KR KR1020087028187A patent/KR20090005195A/ko not_active Withdrawn
- 2007-04-18 MX MX2008013308A patent/MX2008013308A/es not_active Application Discontinuation
- 2007-04-18 BR BRPI0711625-0A patent/BRPI0711625A2/pt not_active IP Right Cessation
- 2007-04-18 US US11/788,032 patent/US8076486B2/en not_active Expired - Fee Related
- 2007-04-18 CA CA002644425A patent/CA2644425A1/en not_active Abandoned
- 2007-04-18 JP JP2009506558A patent/JP5525812B2/ja not_active Expired - Fee Related
- 2007-04-18 EP EP07755648A patent/EP2013180A1/en not_active Withdrawn
- 2007-04-18 EA EA200802050A patent/EA200802050A1/ru unknown
- 2007-04-18 WO PCT/US2007/009456 patent/WO2007123936A1/en not_active Ceased
- 2007-04-19 AR ARP070101677A patent/AR060807A1/es unknown
-
2008
- 2008-10-06 IL IL194546A patent/IL194546A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP2013180A1 (en) | 2009-01-14 |
| ZA200807263B (en) | 2009-11-25 |
| US20070287737A1 (en) | 2007-12-13 |
| CN103121996B (zh) | 2015-10-21 |
| US8076486B2 (en) | 2011-12-13 |
| AR060807A1 (es) | 2008-07-16 |
| WO2007123936A1 (en) | 2007-11-01 |
| JP2009534386A (ja) | 2009-09-24 |
| CA2644425A1 (en) | 2007-11-01 |
| IL194546A0 (en) | 2009-08-03 |
| JP5525812B2 (ja) | 2014-06-18 |
| AU2007240860A1 (en) | 2007-11-01 |
| HK1127354A1 (en) | 2009-09-25 |
| EA200802050A1 (ru) | 2009-04-28 |
| KR20090005195A (ko) | 2009-01-12 |
| CN103121996A (zh) | 2013-05-29 |
| CN101426766A (zh) | 2009-05-06 |
| BRPI0711625A2 (pt) | 2011-12-06 |
| CN101426766B (zh) | 2014-03-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2008013308A (es) | Nuevos derivados de arilaminopiridina heteroaril-sustituidos como inhibidores de mek. | |
| JP4805916B2 (ja) | 化合物、組成物、および方法 | |
| ES2605388T3 (es) | Compuesto inhibidor de Trk | |
| AU2009327357B2 (en) | Pyrazine derivatives useful as inhibitors of ATR kinase | |
| AU2016375634B2 (en) | Bicyclic hydroxamic acids useful as inhibitors of mammalian histone deacetylase activity | |
| CN114573575A (zh) | 一类含氧五元杂环化合物、合成方法、药物组合物及用途 | |
| AU2022265301B2 (en) | Compounds and their uses as cd38 inhibitors | |
| KR20120088738A (ko) | 칼슘 방출-활성화 칼슘 통로의 조정제로서의 피라졸 유도체 | |
| CA2985542A1 (en) | Triazole agonists of the apj receptor | |
| AU2008319308A1 (en) | P2X3, receptor antagonists for treatment of pain | |
| AU2009256574A1 (en) | 2,4'-bipyridinyl compounds as protein kinase D inhibitors useful for the treatment of IA heart failure and cancer | |
| AU2017290705B2 (en) | Compounds and compositions for the treatment of cancer | |
| WO2012020820A1 (ja) | ヘテロアリール－ピラゾール誘導体 | |
| JP2013514287A (ja) | スフィンゴシンキナーゼの阻害薬 | |
| Phillips et al. | Synthesis and antibacterial activities of N-substituted-glycinyl 1H-1, 2, 3-triazolyl oxazolidinones | |
| CA3166630A1 (en) | Polycyclic amides as ube2k modulators for treating cancer | |
| ES2370529T3 (es) | Derivados de benzamida y de pirilamida como agentes antibacterianos. | |
| JP2012500223A (ja) | Ｍａｐキナーゼインヒビターとしての尿素誘導体 | |
| WO2021127301A1 (en) | 4-phenyl-n-(phenyl)thiazol-2-amine derivatives and related compounds as aryl hydrocarbon receptor (ahr) agonists for the treatment of e.g. angiogenesis implicated or inflammatory disorders | |
| TW201245187A (en) | Pyrazole derivatives | |
| CN117820236A (zh) | 组蛋白乙酰转移酶小分子抑制剂及其制备方法和用途 | |
| Guda et al. | An efficient synthesis of styryl 1, 3, 4-thiadiazoles using Lawesson’s reagent and Propylphosphonic anhydride-precursors for bis heterocycles | |
| AU2020264679B2 (en) | Selective ligands of human constitutive androstane receptor | |
| GB2640329A (en) | Hedgehog acyltransferase inhibitors | |
| AU2024248264A1 (en) | Novel azabicycle derivatives and pharmaceutical composition for inhibiting autotaxin, comprising same |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |